186 related articles for article (PubMed ID: 19296223)
21. Impact of Medicaid Restrictions on Availability of Buprenorphine in Addiction Treatment Programs.
Andrews CM; Abraham AJ; Grogan CM; Westlake MA; Pollack HA; Friedmann PD
Am J Public Health; 2019 Mar; 109(3):434-436. PubMed ID: 30676789
[TBL] [Abstract][Full Text] [Related]
22. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
[TBL] [Abstract][Full Text] [Related]
23. Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.
Aletraris L; Bond Edmond M; Roman PM
J Stud Alcohol Drugs; 2015 Jan; 76(1):143-51. PubMed ID: 25486403
[TBL] [Abstract][Full Text] [Related]
24. Adoption and implementation of new technologies in substance abuse treatment.
Roman PM; Johnson JA
J Subst Abuse Treat; 2002 Jun; 22(4):211-8. PubMed ID: 12072165
[TBL] [Abstract][Full Text] [Related]
25. Stepping into the wide world.
Anderson D
Sci Pract Perspect; 2004 Aug; 2(2):3. PubMed ID: 18552727
[No Abstract] [Full Text] [Related]
26. An integrated program of buprenorphine in the primary care setting for HIV(+) persons in Rhode Island.
Mitty J; Macleod C; Loewenthal H; Thompson L; Bazerman L
Med Health R I; 2007 May; 90(5):145-7. PubMed ID: 17557657
[No Abstract] [Full Text] [Related]
27. Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.
Stein BD; Pacula RL; Gordon AJ; Burns RM; Leslie DL; Sorbero MJ; Bauhoff S; Mandell TW; Dick AW
Milbank Q; 2015 Sep; 93(3):561-83. PubMed ID: 26350930
[TBL] [Abstract][Full Text] [Related]
28. Buprenorphine for office-based treatment of patients with opioid addiction.
Manlandro JJ
J Am Osteopath Assoc; 2005 Jun; 105(6 Suppl 3):S8-13. PubMed ID: 16118361
[TBL] [Abstract][Full Text] [Related]
29. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders.
McCann DJ
Clin Pharmacol Ther; 2008 Apr; 83(4):627-30. PubMed ID: 18212797
[TBL] [Abstract][Full Text] [Related]
30. Opioid drugs in maintenance and detoxification treatment of opiate addiction; proposed modification of dispensing restrictions for buprenorphine and buprenorphine combination as used in approved opioid treatment medications. Final rule.
Substance Abuse and Mental Health Services Administration (SAMHSA), Department of Health and Human Services (HHS)
Fed Regist; 2012 Dec; 77(235):72752-61. PubMed ID: 23227572
[TBL] [Abstract][Full Text] [Related]
31. Low Rates of Adoption and Implementation of Rapid HIV Testing in Substance Use Disorder Treatment Programs.
Frimpong JA; D'Aunno T; Helleringer S; Metsch LR
J Subst Abuse Treat; 2016 Apr; 63():46-53. PubMed ID: 26810130
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.
Mamakwa S; Kahan M; Kanate D; Kirlew M; Folk D; Cirone S; Rea S; Parsons P; Edwards C; Gordon J; Main F; Kelly L
Can Fam Physician; 2017 Feb; 63(2):137-145. PubMed ID: 28209683
[TBL] [Abstract][Full Text] [Related]
33. Buprenorphine and addiction: challenges for the pharmacist.
Boatwright DE
J Am Pharm Assoc (Wash); 2002; 42(3):432-8. PubMed ID: 12030630
[TBL] [Abstract][Full Text] [Related]
34. Buprenorphine: blending practice and research.
Ling W; Smith D
J Subst Abuse Treat; 2002 Sep; 23(2):87-92. PubMed ID: 12220606
[TBL] [Abstract][Full Text] [Related]
35. Agency offers guidance on office-based drug treatment for opioid addiction.
Mitka M
JAMA; 2003 Feb; 289(6):690. PubMed ID: 12585931
[No Abstract] [Full Text] [Related]
36. Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine.
Mendelson J; Flower K; Pletcher MJ; Galloway GP
Exp Clin Psychopharmacol; 2008 Oct; 16(5):435-41. PubMed ID: 18837640
[TBL] [Abstract][Full Text] [Related]
37. Bupreorphine:a new pharmacotherapy for opioid addictions treatment.
Stock C; Shum JH
J Pain Palliat Care Pharmacother; 2004; 18(3):35-54. PubMed ID: 15364630
[TBL] [Abstract][Full Text] [Related]
38. Managing opioid addiction with buprenorphine.
Donaher PA; Welsh C
Am Fam Physician; 2006 May; 73(9):1573-8. PubMed ID: 16719249
[TBL] [Abstract][Full Text] [Related]
39. Drug test results as a predictor of retention among patients using buprenorphine in a comprehensive outpatient treatment program.
Campbell MD; Kolodner G; Spencer RA; DuPont RL
J Addict Dis; 2016; 35(4):315-324. PubMed ID: 26757093
[TBL] [Abstract][Full Text] [Related]
40. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.
Arfken CL; Johanson CE; di Menza S; Schuster CR
J Subst Abuse Treat; 2010 Sep; 39(2):96-104. PubMed ID: 20598829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
